New drug combo shows promise against Hard-to-Treat prostate cancer
NCT ID NCT05960578
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostate cancer took part. The main goal was to see if PSA levels dropped by at least half. This approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.